11 subscribers
انتقل إلى وضع عدم الاتصال باستخدام تطبيق Player FM !
المدونة الصوتية تستحق الاستماع
برعاية


1 Amy Schumer & Brianne Howey on the Importance of Female Friendships, Navigating Hollywood's Double Standards, Sharing Their Birth Stories, and MORE 50:05
Fierce's forecasts for the next year in biopharma
Manage episode 461593818 series 3386301
Following the strange year for the biopharma industry that was 2024, insiders and analysts alike are waiting expectantly to see how trends in layoffs, drug shortages, clinical trials and more play out in 2025. Meanwhile, a second Trump term and a spree of related health agency nominations raise serious questions about how health policy could shift over the next 12 months and beyond.
In this week’s episode of “The Top Line,” we explore the trends that defined the industry in 2024 and tackle predictions about how 2025 could shake out for biopharmas big and small. Fierce Pharma’s Fraiser Kansteiner and Fierce Biotech’s Gabrielle Masson discuss 2024’s layoff count, the state of GLP-1 supplies, the future of clinical trial research, potential policy shakeups and more.
To learn more about the topics in this episode:
This episode is brought to you by Cencora. Learn more at cencora.com/breakthrough.
See omnystudio.com/listener for privacy information.
102 حلقات
Manage episode 461593818 series 3386301
Following the strange year for the biopharma industry that was 2024, insiders and analysts alike are waiting expectantly to see how trends in layoffs, drug shortages, clinical trials and more play out in 2025. Meanwhile, a second Trump term and a spree of related health agency nominations raise serious questions about how health policy could shift over the next 12 months and beyond.
In this week’s episode of “The Top Line,” we explore the trends that defined the industry in 2024 and tackle predictions about how 2025 could shake out for biopharmas big and small. Fierce Pharma’s Fraiser Kansteiner and Fierce Biotech’s Gabrielle Masson discuss 2024’s layoff count, the state of GLP-1 supplies, the future of clinical trial research, potential policy shakeups and more.
To learn more about the topics in this episode:
This episode is brought to you by Cencora. Learn more at cencora.com/breakthrough.
See omnystudio.com/listener for privacy information.
102 حلقات
كل الحلقات
×
1 Research reveals ‘ticking DNA clock’ behind Huntington’s disease 19:28

1 What were the biggest clinical trial flops of 2024? 10:17

1 A heartwarming roundup of cardiovascular news and most-loved stories 12:05

1 Looking ahead at the most anticipated drug launches of 2025 14:07

1 What to expect from the biotech IPO market in 2025 34:06

1 Recapping the 2025 J.P. Morgan Healthcare Conference 20:47

1 Fierce's forecasts for the next year in biopharma 25:10

1 An additional treatment option with TAGRISSO® (osimertinib) (Sponsored) 14:25

1 Breaking down the 55 new drug approvals of 2024 13:03

1 Fierce 50 honorees look ahead: AI, rural health, antibiotic resistance, maternal care and more 39:41

1 Novo Nordisk’s chief scientific officer looks to the future of GLP-1s 32:45

1 What can we learn from 2024’s biotech IPOs? 15:06

1 Meet 2024’s fiercest women in life sciences 12:30

1 Misconduct and the future of neurodegenerative disease research 15:29

1 Dig into this year’s Fierce Biotech Graveyard, layoff numbers 11:51
مرحبًا بك في مشغل أف ام!
يقوم برنامج مشغل أف أم بمسح الويب للحصول على بودكاست عالية الجودة لتستمتع بها الآن. إنه أفضل تطبيق بودكاست ويعمل على أجهزة اندرويد والأيفون والويب. قم بالتسجيل لمزامنة الاشتراكات عبر الأجهزة.